Urothelial Carcinoma Clinical Trial
Official title:
Feasibility of Confocal Laser Endomicroscopy in Bladder Cancer Diagnosis
Rationale: Cystoscopy and cytology, the current 'gold standard' for detection and follow-up
of primary and recurrent bladder cancer have some limitations. CLE, a high resolution imaging
technique, that can be used combined with endo-urological procedures, seems promising to
improve diagnosis of bladder cancer. The diagnostic accuracy of cystoscopic applied confocal
laser endomicroscopy (CLE) still has to be defined.
Objective: To directly correlate CLE images with histopathology, and identify and define CLE
characteristics of normal urothelium, benign bladder urothelium, and bladder tumors
(low-grade, high-grade and carcinoma in situ (CIS)) of the lower urinary tract.
Primary objective: to develop descriptive image interpretation criteria and a classification
of CLE images of bladder tissue through a review of prospectively obtained CLE videos from
bladder tissue correlated with histopathology.
Secondary objectives:
- Assessing procedure related adverse events of CLE
- Assessing technical feasibility of CLE
- To develop a CLE image atlas for urothelium of the lower urinary tract (normal, benign,
low-grade or high-grade and CIS)
This is a prospective, multicenter, observational study; the investigators will establish
sensitivity and specificity of CLE ex vivo and in vivo, in the diagnosis of bladder
carcinoma.
Eligible patients are diagnosed with a bladder tumor at the outpatient clinic and scheduled
for transurethral resection of bladder tumor (TURB). In total the investigators want to
include 60 patients. Yearly approximately 70 patients are diagnosed with primary and
recurrent bladder carcinoma in the Academic Medical Center (AMC) and will undergo TURB.
Their Urologist will inform patients diagnosed with a bladder tumor who will be scheduled for
treatment by means of TURB about the study. Information about the study will be provided both
orally and in written form.
CLE images are recorded using a probe-based system (Cellvizio 100 series, Mauna Kea
Technologies, Paris, France). The probe (Cystoflex UHD-R, Mauna Kea Technologies, Paris,
France) has an outer diameter of 2.8 mm, a field of view of 240 µm and has a resolution of 1
µm. Images are collected at a scan rate of 12 frames per second. Using the Cellvizio Viewer
system, the investigators can observe mucosal microarchitecture with an increased field of
view through mosaic post processing. This system also enables virtual staining of mucosal
structures to further enhance tissue contrast.
A fluorescent contrast agent is needed to obtain CLE images. Fluorescein
(fluoresceinedisodium, Fresenius Kabi, Zeist, Netherlands), a non-toxic and commonly used
fluorescent dye will be administered intravesical (300-400 mL 0.1% fluorescein diluted in
saline) and left indwelling for 5 minutes to stain the extracellular matrix.
The study consists of three CLE measurements, one in vivo prior to tumor resection, the
second ex vivo of the resected specimen, and the last measurement is ex vivo after fixating
the tumor on formaldehyde. In the case of multiple tumors, multiple CLE measurements will be
done. The measurement per-operatively will add approximately 15 minutes to operating time. In
the ex vivo set up, additional images will be acquired using Optical Coherence Tomography
(OCT). During tumor resection, a small chip of normal urothelium will be resected
additionally to act as control. Resected bladder tissue will be fixed and laminated by the
pathology department, to correlate to CLE images.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
Recruiting |
NCT05775874 -
A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC
|
Phase 2 | |
Recruiting |
NCT04623502 -
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
|
N/A | |
Recruiting |
NCT04617756 -
Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract
|
Phase 2 | |
Recruiting |
NCT06116396 -
Liquid Biospy for Urinary Cancers
|
||
Recruiting |
NCT05723991 -
Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma
|
Phase 4 | |
Active, not recruiting |
NCT03039413 -
Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy
|
Early Phase 1 | |
Completed |
NCT02795156 -
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
|
Phase 2 | |
Terminated |
NCT03915405 -
KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Completed |
NCT04452214 -
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
|
Phase 1 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT05911295 -
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
|
Phase 3 | |
Terminated |
NCT01093066 -
Prospective Multicentric Evaluation of a Bladder Preservation Strategy
|
Phase 2 | |
Terminated |
NCT01042795 -
Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
|
Phase 2 | |
Recruiting |
NCT06022757 -
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
|
Phase 1/Phase 2 | |
Recruiting |
NCT03212404 -
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 |